Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy
Lake, Jordan E;for the ACTG A5322 Study Team;Wu, Kunling;for the ACTG A5322 Study Team;Bares, Sara H;for the ACTG A5322 Study Team;Debroy, Paula;for the ACTG A5322 Study Team;Godfrey, Catherine;for the ACTG A5322 Study Team;Koethe, John R;for the ACTG A5322 Study Team;McComsey, Grace A;for the ACTG A5322 Study Team;Palella, Frank J;for the ACTG A5322 Study Team;Tassiopoulos, Katherine;for the ACTG A5322 Study Team;Erlandson, Kristine M;for the ACTG A5322 Study Team;
clinical infectious diseasespp. -
214
eclinicalrisk
Abstract
We report the first data on within-person weight trajectories following switch to integrase inhibitor-based antiretroviral therapy while virologically suppresse